其核心思想是借鉴计算机科学中的“外存算法” (Out-of-core algorithms)，不要把长 Prompt 直接喂给神经网络，而是把它放在一个外部的 Python REPL 环境里。 Prompt 被加载为环境中的变量context 。模型不再像以前那样生吞整个字符串，而是通过编写代码（如len (context) , context.split , re.search ）来按需读取数据 ...

How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

The native just-in-time compiler in Python 3.15 can speed up code by as much as 20% or more, although it’s still experimental ...

In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...

Recursion Pharmaceuticals' work could change the way that drugs are developed. Its pipeline features some exciting candidates, and it's partnering with major drugmakers. However, Recursion still needs ...

We recently published 12 Best Healthcare Stocks to Buy Under $30. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the best healthcare stocks. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is a ...

RXRX stock looks like a deep-value growth bet at just $5 and change. Though the technology is exciting, I’m not rushing into shares just yet. Nvidia made early investors rich, but there is a new class ...

The business of using artificial intelligence to find new drugs is starting to consolidate. The AI-powered drug discovery firm Recursion Pharmaceuticals will buy rival Exscientia in an all-stock deal ...

Recursion is using artificial intelligence and machine learning to accelerate drug research and development. The company benefits from partnerships with major tech and healthcare leaders, reaffirming ...

Abstract: Memoization is a computational technique for speeding up the complexity of computer algorithms. It stores the previously calculated results and invokes them later in the body of the ...

The merger is anticipated to bolster therapeutic discovery collaborations. Credit: Max Acronym/Shutterstock. Recursion has agreed to merge with Exscientia to create a global technology-enabled drug ...